Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Brian Edward Lavan"'
Autor:
Fang Zhang, Dennis Rentzeperis, Francine M. Gregoire, Holly J. Clarke, Brian Edward Lavan, Thomas A. Gustafson, Svetlana Favelyukis, Dorothy D. Sears, L. Edward Clemens, James M. Lenhard, Yi Mu
Publikováno v:
Molecular Endocrinology. 23:975-988
MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d5a0582832e3857944e294f2920342f
https://doi.org/10.1210/me.2008-0473
https://doi.org/10.1210/me.2008-0473
Autor:
Brian Edward Lavan, Fang Ma, Holly J. Clarke, Robert Martin, Francine M. Gregoire, Spring Zhao
Publikováno v:
PPAR Research, Vol 2008 (2008)
PPAR Research
PPAR Research
Drug binding to plasma proteins restricts their free and active concentrations, thereby affecting their pharmacokinetic properties. Species differences in plasma protein levels complicate the understanding of interspecies pharmacodynamic and toxicolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::751f938df0ae47abc895daba64ed2bed
https://doi.org/10.1155/2008/465715
https://doi.org/10.1155/2008/465715
Autor:
Vic Vicena, Apurva Chandalia, Holly J. Clarke, Brian Edward Lavan, Paul Lee, Francine M. Gregoire, L. Edward Clemens, Bindu Pandey
Publikováno v:
PPAR Research
PPAR Research, Vol 2009 (2009)
PPAR Research, Vol 2009 (2009)
MBX-102/JNJ-39659100 (MBX-102) is a selective, partial PPAR- 𝛾 agonist that lowers glucose in the absence of some of the side effects, such as weight gain and edema, that are observed with the TZDs. Interestingly MBX-102 also displays pronounced t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96f04822053ef71c48b1883b0b5262b7
Publikováno v:
PPAR Research, Vol 2007 (2007)
PPAR Research
PPAR Research
Peroxisome proliferator-activated receptorγ(PPAR-γ) is a key regulator of lipid metabolism and energy balance implicated in the development of insulin resistance and obesity. The identification of putative natural and synthetic ligands and activato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d0c92a56ce0aa84f7a16b19fba7bad
https://doaj.org/article/195b5c68cdc34436bba018790aee7ce7
https://doaj.org/article/195b5c68cdc34436bba018790aee7ce7
Autor:
Thomas A. Gustafson, Yi Mu, L. Edward Clemens, Francine M. Gregoire, James M. Lenhard, Dorothy D. Sears, Svetlana Favelyukis, Dennis Rentzeperis, Brian Edward Lavan, Fang Zhang, Holly J. Clarke
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 94:2210-2210
MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose lowering agent for the treatment of type 2 diabetes. MBX-102 is a non-thiazolidinedione (TZD) selective partial agonist of PPAR-γ that is differentiated from the TZDs struct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c618b98c459d08f19065b9720a4dca7
https://doi.org/10.1210/jcem.94.6.9995
https://doi.org/10.1210/jcem.94.6.9995
Publikováno v:
Drug News & Perspectives. 17:661
The peroxisome proliferator-activated receptors (PPARs) alpha, delta and gamma are a group of ligand-activated transcription factors that function as lipid sensors and govern numerous biological processes, including energy metabolism, cell proliferat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d669fab5014ca2914fa459d3cfb5b8
https://doi.org/10.1358/dnp.2004.17.10.873918
https://doi.org/10.1358/dnp.2004.17.10.873918